tirzepatide pdufa date The is locked in for LGMD2I/R9. The FDA has accepted our NDA for BBP-418 for LGMD2I/R9, with a target action date of November 27, 2026. For a community that has Q1 2026 Biotech Catalyst Calendar:

For Whom Might Each Drug Be More Suitable Tirzepatide could be more effective for: Adults with obesity or high BMI who need substantial weight loss ( 1525%)

But because retatrutide is still investigational, dosing schedules may change once phase 3 data are available

Keep a daily log that includes: Injection date, time, dose, and site Appetite level on a 1 to 10 scale Energy level on a 1 to 10 scale GI symptoms (nausea, bloating, constipation, diarrhea) with severity rating Weight (same time each morning, same conditions) Notable observations (food cravings, mood changes, sleep quality) After two to four weeks at each dose level, review your log for patterns

While this study did not include metformin as background therapy, it established tirzepatide's independent weight loss efficacy (up to 22.5% body weight reduction with the 15 mg dose at 72 weeks)

Patients must thoroughly discuss with their providers to pick the best one for them based on their health, side effects, and cost